Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis
- PMID: 27664282
- PMCID: PMC5038228
- DOI: 10.1128/AAC.00705-16
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis
Abstract
We describe a pediatric cystic fibrosis patient who developed a pulmonary exacerbation due to two multidrug-resistant (MDR) Pseudomonas aeruginosa isolates. In addition to these MDR organisms, the case was further complicated by β-lactam allergy. Despite the MDR phenotype, both isolates were susceptible to an antimicrobial combination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
References
-
- Merck & Co., Inc. 2015. Product information: Zerbaxa intravenous injection, ceftolozane/tazobactam intravenous injection. Merck & Co., Inc., Whitehouse Station, NJ.
-
- Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP. 2015. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis 83:53–55. doi: 10.1016/j.diagmicrobio.2015.04.012. - DOI - PubMed
-
- Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. 2014. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 58:6311–6314. doi: 10.1128/AAC.03572-14. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
